iBio (IBIO) announced the appointment of biotech industry veterans David Arkowitz and Antonio Parada to its Board of Directors adding key experience in finance, leadership and antibody discovery. Arkowitz is currently Chief Financial Officer at Alkeus Pharmaceuticals, a private company developing therapies for serious diseases of the eye with high unmet need. Parada is the Founder and CEO of FairJourney Biologics, a privately held and leading antibody discovery contract research organization
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on IBIO:
- iBio reports Q1 EPS (46c), consensus (48c)
- iBio Unveils AI-Driven Antibody Discovery Strategy
- Biotech Alert: Searches spiking for these stocks today
- iBio, AstralBio provide update on myostatin program for obesity
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
